# MabionCD20 Compared to MabThera in Lymphoma Patients

> **NCT02617485** · PHASE3 · COMPLETED · sponsor: **Mabion SA** · enrollment: 143 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT02617485
- **Lead sponsor:** Mabion SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-08
- **Final completion:** 2018-01
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02617485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02617485, "MabionCD20 Compared to MabThera in Lymphoma Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02617485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*